USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Epitope Inc.
Address:
15425-e Sw Koll Parkway
Beaverton, OR 97006
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $194,887.00 4
SBIR Phase II $874,218.00 2

Award List:

DETECTION OF AIDS VIRUS (HTLV-III) BY MONOCLONAL ANTIBODIES

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Denis R Burger , Principal Investigator
Abstract:
N/a

ETHYLTHIORIBOSE: A NEW ANTIFUNGAL AGENT

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Adolph j ferro phd
Abstract:
The incidence of fungal infections has increased markedly since the advent of broad-spectrum antibiotics, corticosteroids, cancer chemotherapy, and organ transplantation. currently available antifungal agents such as amphotericin b are often avoided clinically because of their severe toxic side… More

DETECTION OF AIDS VIRUS (HTLV-III) BY MONOCLONAL ANTIBODIES

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$406,000.00
Agency:
HHS
Principal Investigator:
Denis R Burger , Principal Investigator
Abstract:
The objective of this proposal is to use mouse monoclonal antibodies to htlv-iii to evaluate the feasibility of detecting htlv antigen expression on t lymphocytes in clinical specimens from patients with lyphadenopathy syndrome and overt aids, and in individuals in high risk groups. this will be… More

A NON-TOXIC NEW DRUG ACTIVE AGAINST GIARDIA IN VIVO.

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Giardiasis is the most prevalent parasitic disease in the united states and ranks as a leading cause of diarrheal illness worldwide. available drugs for the treatment of giardiasis have undesirable side-effects and may be carcinogenic. we have found that the method by which giardia degrade the… More

RAPID ASSAY FOR HIV-1 ANTIBODIES IN SALIVA

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$44,887.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

RAPID ASSAY FOR HIV-1 ANTIBODIES IN SALIVA

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$468,218.00
Agency:
HHS
Principal Investigator:
Abstract:
There is a need for an hiv-i antibody test that is specifically designed for field use with saliva and that is rapid, accurate, convenient, and inexpensive. such a test would be especially valuable in work with i.v. drug abusers and prostitutes, where time with the patient is brief and followup is… More